ATAD2 and colorectal cancer: Beyond TNBC, ATAD2 deletion in colorectal cancer (CRC) cells reduces expression of cyclin D1, pRb, E2F1, and cyclin E, suggesting that the ATAD2–B-MYB axis is a conserved driver of oncogenic cell cycle control across multiple tumor types [66].